Plus, news about Zenas and Ysios Capital: 🌀 AnaptysBio’s spinout: The independent public company, called First Tracks Biotherapeutics, is expected to start trading on April

A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated

Recordati has received a takeover offer from private equity group CVC that, if completed, would delist it from the Italian stock exchange.

AZ’s IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the

New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma